Document is current
Any future updates will be listed below
-
Authors
Östör, Andrew https://orcid.org/0000-0002-7929-4827
Van den Bosch, Filip https://orcid.org/0000-0002-3561-5932
Papp, Kim https://orcid.org/0000-0001-9557-3642
Keiserman, Mauro
Blanco, Ricardo https://orcid.org/0000-0003-2344-2285
Crowley, Angela https://orcid.org/0009-0007-5513-7572
White, Douglas https://orcid.org/0000-0003-0839-8511
Biljan, Ana
Madihlaba, Tshepiso https://orcid.org/0000-0003-1343-7757
Carter, Kyle
Liu, Fang
Soliman, Ahmed M. https://orcid.org/0009-0008-8632-1396
Ashley, Doug
Chen, Michael https://orcid.org/0000-0002-8773-0879
Glotfelty, Lila https://orcid.org/0000-0002-6973-7516
Kivitz, Alan https://orcid.org/0000-0002-1045-1310
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03675308 at ClinicalTrials.govnct03671148 at ClinicalTrials.govDocuments that mention this clinical trial
POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1
https://doi.org/10.1136/annrheumdis-2022-eular.1186
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
https://doi.org/10.1136/rmdopen-2025-005522
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
https://doi.org/10.1007/s40744-025-00793-3
AB0559 EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2678
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
Documents that mention this clinical trial
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
https://doi.org/10.1136/rmdopen-2022-002286
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
https://doi.org/10.1136/rmdopen-2025-005522
OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2695
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2
https://doi.org/10.1136/annrheumdis-2022-eular.1673
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
https://doi.org/10.1007/s40744-025-00793-3
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 15 August 2025
First Online: 30 September 2025
Declarations
:
: Andrew Östör has received speaker or consulting fees and/or research grants from AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. Filip Van den Bosch has received speaker and/or consulting fees from AbbVie, Alfasigma, Celgene by Amgen, Fresenius Kabi, Galapagos, Janssen, Lilly, Novartis, and UCB. Kim Papp has received honoraria and/or grants from, is a consultant, investigator, or a scientific officer for AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite BioPharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DICE Therapeutics, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. Mauro Keiserman has served as a speaker for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; was a consultant for AbbVie, Biogen, Bristol Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Sanofi; and receives grant/research support from AbbVie, Biogen, Bristol Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Sanofi. Ricardo Blanco has received grants or research support from AbbVie, Merck, and Roche. He has received consultation fees or honoraria for serving as a speaker for AbbVie, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, and Roche. Angela Crowley has received research funds, honoraria, or fees for serving as a consultant or speaker from AbbVie, Acelyrin, Amgen, AstraZeneca, GlaxoSmithKline, Kiowa-Kirin, Janssen, Lilly, Novartis, SetPoint Medical, and UCB. Douglas White has received honoraria or fees for serving on advisory boards or as a speaker or consultant from AbbVie. Alan Kivitz has received consulting fees from Frescenius Kabi, Genzyme, Gilead, GlaxoSmithKline, Grünenthal, Horizon, Janssen, Pfizer, Selecta, SynAct, and Takeda; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB; has served on boards or advisory boards for Biopartners, ChemoCentryx, Horizon, Janssen, Novartis, Princeton, and UCB; and has stock or stock options in Amgen, GlaxoSmithKline, Gilead, Novartis, and Pfizer. Doug Ashley, Ana Biljan, Kyle Carter, Michael Chen, Fang Liu, Tshepiso Madihlaba, Ahmed M. Soliman, and Lila Glotfelty are employees of AbbVie Inc., and may own stock/stock options and patents in the company. We thank the participants of the study. The authors would like to thank all the trial investigators for their contribution and the patients who participated in this trial.
: The Independent Ethics Committee or Institutional Review Board at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The coordinating investigators for KEEPsAKE 1 (Lars Erik Kristensen of the Parker Institute, Frederiksberg, Denmark) and KEEPsAKE 2 (Alan Kivitz of the Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA) received approval from the Danish Health Research Ethics Committee and the Quorum International Review Board, respectively. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent before screening.
